The Effect of Ivabradine on the Heart Rate and Sympathovagal Balance in Postural Tachycardia Syndrome Patients
Open Access
- 30 July 2015
- journal article
- Published by Rambam Health Corporation in Rambam Maimonides Medical Journal
- Vol. 6 (3), e0028
- https://doi.org/10.5041/rmmj.10213
Abstract
Postural tachycardia syndrome (POTS) is a common form of chronic orthostatic intolerance. The remarkable increase in heart rate (HR) upon standing is the hallmark of this syndrome. Treatment of POTS patients is challenging and includes drugs that slow the HR. Ivabradine is a selective If channel blocker designed to slow the HR, as an anti-anginal agent. In view of its ability to slow the HR, we posited that ivabradine may be an ideal medication for treating POTS patients. This report provides the results of an investigation in which we studied ivabradine’s effect on the hemodynamics and sympathovagal balance in POTS patients. An open-label trial, without a placebo control, was performed in eight patients with POTS of two years’ standing. Characterization of symptoms, hemodynamics, autonomic function tests, and HR and blood pressure (BP) variability were determined while patients were in a supine position and during a 20-minute head-up tilt before and after a single oral dose of 7.5 mg ivabradine. Ivabradine slowed the HR of POTS patients at rest by 4±1 bpm (P<0.05). During a 5-minute head-up tilt, the HR decreased from 118±4 bpm to 101±5 bpm (P<0.01). Ivabradine did not affect the BP when patients were at rest in a supine position or in head-up tilt position. Cardiovascular vagal and sympathetic tone, extrapolated from the time and frequency domains of the HR and BP variability, were also not affected by ivabradine. Ivabradine is an effective drug for slowing the HR of POTS patients at rest and during tilting, without producing significant adverse effects. Moreover, ivabradine exerts its effects without influencing the sympathovagal balance.Keywords
This publication has 37 references indexed in Scilit:
- Differential effects of heart rate reduction by atenolol or ivabradine on peripheral endothelial function in type 2 diabetic patientsHeart, 2012
- Ivabradine in the treatment of orthostatic intoleranceEP Europace, 2011
- Ivabradine and outcomes in chronic heart failure.The Lancet, 2010
- Joint Hypermobility Syndrome and Dysautonomia: Expanding Spectrum of Disease Presentation and Manifestation2010
- Postural Tachycardia Syndrome (POTS)Journal of Cardiovascular Electrophysiology, 2009
- Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trialThe Lancet, 2008
- Efficacy of ivabradine, a new selective If inhibitor, compared with atenolol in patients with chronic stable anginaEuropean Heart Journal, 2005
- Heart Rate Lowering by Specific and Selective If Current Inhibition with IvabradineDrugs, 2004
- Orthostatic Intolerance and Tachycardia Associated with Norepinephrine-Transporter DeficiencyThe New England Journal of Medicine, 2000
- Abnormal Norepinephrine Clearance and Adrenergic Receptor Sensitivity in Idiopathic Orthostatic IntoleranceCirculation, 1999